Chanda Sanjay 4
4 · AN2 Therapeutics, Inc. · Filed Feb 23, 2026
Research Summary
AI-generated summary of this filing
AN2 Therapeutics (ANTX) CDO Chanda Sanjay Receives RSU Awards
What Happened Chanda Sanjay, Chief Development Officer of AN2 Therapeutics (ANTX), received equity awards on February 20, 2026: 38,000 restricted stock units (RSUs) (grant reported as A) and 77,000 RSU-style derivative units (reported as A/derivative). Both awards are reported at $0.00 per share (typical for compensation awards), totaling 115,000 shares granted. These are awards/compensation grants rather than open-market purchases or sales.
Key Details
- Transaction date: February 20, 2026; Form 4 filed February 23, 2026 (appears timely).
- Price: $0.00 per share for both grants (award/compensation).
- Total shares granted: 38,000 (A) + 77,000 (A, derivative) = 115,000.
- Shares owned after transaction: not specified in the excerpt provided; the filing notes an adjusted total that includes a prior ESPP purchase (see F3).
- Footnotes of note:
- F1: The 38,000 RSUs vest 1/4 annually over four years starting January 1, 2026, subject to continued service.
- F2: The 77,000 derivative award "includes a balance" described as (a) 27,500 RSUs vesting 1/4 annually from Jan 1, 2024 and (b) 50,250 RSUs vesting 1/4 annually from Jan 1, 2025, each subject to continued service.
- F3: The filing’s adjusted total reflects a purchase of 5,000 shares under the issuer’s 2022 ESPP on March 31, 2025.
- F4: Separate option holdings (if any) vest 1/48th monthly over four years from Jan 1, 2026, subject to continued service.
- No sale or open-market purchase; this is a compensation grant (generally considered routine).
Context RSU awards reported at $0 indicate compensation-based grants that vest over time and require the executive’s continued service to the company; they are not immediate cash or market trades. Derivative-designated entries here refer to RSUs/other equity-based awards with specific vesting schedules (see F1–F2). For retail investors, such grants are common for executive compensation and do not by themselves indicate a buy or sell signal.
Insider Transaction Report
- Award
Common Stock
[F1][F2][F3]2026-02-20+38,000→ 118,823 total - Award
Stock Option (right to buy)
[F4]2026-02-20+77,000→ 77,000 totalExercise: $1.04Exp: 2036-02-19→ Common Stock (77,000 underlying)
Footnotes (4)
- [F1]Represents restricted stock units ("RSUs") which vest as follows: 1/4th of the shares vests annually over four years from January 1, 2026, subject to the Reporting Person's continuous service through each applicable vesting date.
- [F2]Includes a balance of (a) 27,500 RSUs which vest as follows: 1/4th of the RSUs vest annually over four years from January 1, 2024 and (b) 50,250 RSUs which vest as follows: 1/4th of the RSUs vest annually over four years from January 1, 2025, in each case subject to the Reporting Person's continuous service through each applicable vesting date.
- [F3]Reflects the adjusted total which includes the purchase of 5,000 shares under the Issuer's 2022 Employee Stock Purchase Plan on March 31, 2025.
- [F4]The shares subject to the option vest as follows: 1/48th of the shares vests monthly over four years from January 1, 2026, subject to the Reporting Person's continuous service through each applicable vesting date.